Solara Active Pharma Sciences Intrinsic Value
Solara Active Pharma Sciences intrinsic value. Solara Active Pharma Sciences (SOLARA) median intrinsic value is ₹315.65 from 8 valuation models (range ₹203–₹699), vs current price ₹676.90 — -53.4% downside (Trading Above Calculated Value), margin of safety -100.0%. For current market price and key ratios, visit SOLARA share price screener.
SOLARA Valuation Methods Summary — DCF, Graham Number & P/E
Solara Active Pharma Sciences intrinsic value across 8 models vs current price ₹676.90 — upside/downside and value range per method. Read SOLARA dividend history for the complete payout history and dividend yield track record.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹203.07 | ₹162.46 - ₹243.68 | -70.0% | EPS: ₹8.80, Sector P/E: 22x |
| Book Value Method | asset | ₹558.22 | ₹502.40 - ₹614.04 | -17.5% | Book Value/Share: ₹279.11, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹698.67 | ₹628.80 - ₹768.54 | +3.2% | Revenue/Share: ₹349.33, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹560.00 | ₹504.00 - ₹616.00 | -17.3% | EBITDA: ₹252.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹315.65 | ₹252.52 - ₹378.78 | -53.4% | CF Growth: 5.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹203.07 | ₹182.76 - ₹223.38 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹203.07 | ₹182.76 - ₹223.38 | -70.0% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| Graham Defensive Method | conservative | ₹235.08 | ₹211.57 - ₹258.59 | -65.3% | EPS: ₹8.80, BVPS: ₹279.11 |
SOLARA Intrinsic Value vs Market Price — All Valuation Models
Solara Active Pharma Sciences fair value range ₹203–₹699 vs current market price ₹676.90 across 8 valuation models. Compare with Solara Active Pharma Sciences value estimation to assess whether the stock is under or overvalued.
SOLARA Intrinsic Value Analysis — Undervalued or Overvalued?
Solara Active Pharma Sciences median intrinsic value ₹315.65, current price ₹676.90 — Trading Above Calculated Value by 53.4%, margin of safety -100.0%.
What is the intrinsic value of SOLARA?
Based on our comprehensive analysis using 8 different valuation methods, the estimated intrinsic value of Solara Active Pharma Sciences (SOLARA) is ₹315.65 (median value). With the current market price of ₹676.90, this represents a -53.4% variance from our estimated fair value.
The valuation range spans from ₹203.07 to ₹698.67, indicating ₹203.07 - ₹698.67.
Is SOLARA undervalued or overvalued?
Based on our multi-method analysis, Solara Active Pharma Sciences (SOLARA) appears to be trading above calculated value by approximately 53.4%.
SOLARA Financial Health — Key Ratios vs Industry Benchmarks
Solara Active Pharma Sciences financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 4.69 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 3.2% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 15.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.67x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
SOLARA Cash Flow Quality — Operating & Free Cash Flow
Solara Active Pharma Sciences operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹153 Cr | ₹104 Cr | Positive Free Cash Flow | 8/10 |
| March 2025 | ₹213 Cr | ₹195 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹109 Cr | ₹107 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹156 Cr | ₹116 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹-242 Cr | ₹-364 Cr | Negative Cash Flow | 3/10 |